Physician profile
Asela D Wickremasinghe
NPI 1164476081
$11,842.89
in general payments reported to CMS, 2019-2025
47 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,191 · 2020: $1,793 · 2021: $2,184 · 2022: $1,491 · 2023: $1,299 · 2024: $1,493 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,183.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,356.88 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,230.43 | 2019-2025 | Jardiance |
| Amgen INC. | $864.92 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $835.05 | 2020-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $711.67 | 2020-2024 | Linzess, Viberzi, Ubrelvy |
| Lilly USA, LLC | $567.71 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $492.33 | 2019-2021 | |
| Mylan Specialty L.P. | $450.14 | 2019-2024 | Yupelri |
| Astellas Pharma US INC | $352.48 | 2019-2025 | Veozah |
| Ironwood Pharmaceuticals, INC | $348.55 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $342.78 | 2019-2024 | Verquvo |
| Ardelyx, INC. | $307.91 | 2024-2025 | Ibsrela |
| Pfizer INC. | $298.72 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $213.91 | 2022 | |
| Janssen Pharmaceuticals, INC | $206.26 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asela Wickremasinghe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.